0001237899-19-000037.txt : 20191213
0001237899-19-000037.hdr.sgml : 20191213
20191213174352
ACCESSION NUMBER: 0001237899-19-000037
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191211
FILED AS OF DATE: 20191213
DATE AS OF CHANGE: 20191213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: VAGELOS P ROY
CENTRAL INDEX KEY: 0001013064
STANDARD INDUSTRIAL CLASSIFICATION: AIRCRAFT [3721]
STATE OF INCORPORATION: MD
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 191285434
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2019-12-11
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001013064
VAGELOS P ROY
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
1
0
0
Chairman of the Board
Common Stock
2019-12-12
4
M
0
107655
21.25
A
412140
D
Common Stock
2019-12-12
4
F
0
55813
377.16
D
356327
D
Common Stock
2019-12-13
4
S
0
632
373.26
D
355695
D
Common Stock
2019-12-13
4
S
0
6873
374.79
D
348822
D
Common Stock
2019-12-13
4
S
0
21910
375.55
D
326912
D
Common Stock
2019-12-13
4
S
0
13060
376.36
D
313852
D
Common Stock
2019-12-13
4
S
0
5732
377.47
D
308120
D
Common Stock
2019-12-13
4
S
0
3602
378.38
D
304518
D
Common Stock
2019-12-13
4
S
0
33
379.14
D
304485
D
Common Stock
2326
I
By 401(k) Plan
Common Stock
144897
I
by CLAT
Common Stock
83652
I
by Spouse as Trustee
Common Stock
1203
I
by trust for grandch
Non-Qualified Stock Option (right to buy)
21.25
2019-12-12
4
M
0
107655
0.0
D
2019-12-18
Common Stock
107655
0
D
Non-Qualified Stock Option (right to buy)
372.46
2019-12-11
4
A
0
29177
0.0
A
2029-12-11
Common Stock
29177
29177
D
Performance Stock Units
2019-12-11
4
A
0
9086
0.0
A
Common Stock
9086
9086
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 632 shares of Company stock on December 13, 2019 at prices ranging from $373.21 to $373.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
Represents volume-weighted average price of sales of 6,873 shares of Company stock on December 13, 2019 at prices ranging from $374.22 to $374.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
Represents volume-weighted average price of sales of 21,910 shares of Company stock on December 13, 2019 at prices ranging from $375.02 to $375.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
Represents volume-weighted average price of sales of 13,060 shares of Company stock on December 13, 2019 at prices ranging from $376.00 to $376.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
Represents volume-weighted average price of sales of 5,732 shares of Company stock on December 13, 2019 at prices ranging from $377.01 to $377.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
Represents volume-weighted average price of sales of 3,602 shares of Company stock on December 13, 2019 at prices ranging from $378.07 to $378.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
Represents volume-weighted average price of sales of 33 shares of Company stock on December 13, 2019 at prices ranging from $379.06 to $379.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 4,038 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires.
By: Beverly Dubs, as attorney-in-fact For: P. Roy Vagelos
2019-12-13